These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12640509)

  • 1. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.
    Portal VL; Moriguchi EH; Vieira J; Schio S; Mastalir ET; Buffé F; Bortolini EB; Brüch RS; Rodrigues R
    Arq Bras Cardiol; 2003 Feb; 80(2):156-61, 150-5. PubMed ID: 12640509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
    Inoue T; Hayashi M; Takayanagi K; Morooka S
    Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
    Yasuhara M; Suzumura K; Tanaka K; Takahashi M; Aoki S; Odawara A; Narita H; Suzuki T
    Biol Pharm Bull; 2000 May; 23(5):570-4. PubMed ID: 10823666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia.
    Zhang B; Noda K; Matsunaga A; Kumagai K; Saku K
    J Atheroscler Thromb; 2005; 12(1):41-7. PubMed ID: 15725695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
    Hussein O; Schlezinger S; Rosenblat M; Keidar S; Aviram M
    Atherosclerosis; 1997 Jan; 128(1):11-8. PubMed ID: 9051193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.
    Martínez-Castelao A; Grinyó JM; Fiol C; Castiñeiras MJ; Hurtado I; Gil-Vernet S; Serón D; Porta I; Miñarro A; Villarroya A; Alsina J
    Kidney Int Suppl; 1999 Jul; 71():S231-4. PubMed ID: 10412785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
    Hussein O; Shneider J; Rosenblat M; Aviram M
    J Cardiovasc Pharmacol; 2002 Jul; 40(1):28-34. PubMed ID: 12072574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals.
    Leonhardt W; Kurktschiev T; Meissner D; Lattke P; Abletshauser C; Weidinger G; Jaross W; Hanefeld M
    Eur J Clin Pharmacol; 1997; 53(1):65-9. PubMed ID: 9349932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
    Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
    Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
    Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
    Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.